NCT00724581

Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer

Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer: A Controlled, Randomized, Double Blinded Trial

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 275 (estimated)
• Sponsor: Aarhus University Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Patients undergoing lung resection due to pulmonary cancer can be compromised in their postoperative period due to atrial fibrillation. A retrospective analysis performed at our institution indicates that 30 % of the population develope atrial fibrillation in the postoperative period. Amiodarone is known to diminish the occurence of postoperative atrial fibrillation after heart surgery, why this drug is chosen as a prophylactic agent for the mentioned population. Amiodarone is administrated twice a day for 5 days at a dose of 600 mg oral treatment after an initial loading bolus og 300 mg intravenously.

Conditions

• Atrial Fibrillation

Interventions

Type	Name	Description
DRUG	Amiodarone	intravenous bolus of 300 mg oral treatment og 600 mg twice a day for five days

Timeline

• Start date: 2008-08-01
• Primary completion: 2009-08-01
• Completion: 2009-12-01
• First posted: 2008-07-29
• Last updated: 2008-07-29

Locations

1 site across 1 country: Denmark